wellrank.ai

Which telehealth services still offer compounded GLP-1s after the FDA crackdown?

ClaudequalifiedCollected Jun 20, 2026, 13:09 UTC

Verbatim response from Claude

This is a fast-moving regulatory area, so I want to be straightforward with you:

Important Context First

The FDA declared the semaglutide shortage over in early 2025, which legally restricts most compounding of semaglutide (Ozempic/Wegovy). Tirzepatide (Mounjaro/Zepbound) shortage status has also changed.

Services That Have Been Navigating This Space

  • Hims & Hers - Was offering compounded semaglutide but faced legal pressure; check their current status
  • Ro (Body Program) - Similar situation, pivoting to brand-name options
  • Henry - Has offered compounded options
  • Mochi Health - Has worked with compounding pharmacies

Honest Caveats

  • Many providers have had to stop or modify their compounded offerings due to FDA enforcement
  • Services advertising compounded semaglutide may be operating in a legal gray area
  • Formulations with added ingredients (B12, etc.) have different rules

My Recommendation

  1. Verify directly with any service before signing up - policies change monthly
  2. Ask specifically what pharmacy compounds it and their FDA compliance status
  3. Consider whether brand-name options with manufacturer coupons (like Eli Lilly's savings program) might be comparable in cost

Would you like help thinking through the brand-name alternatives instead?

Brands mentioned in this answer

Is this answer wrong about your brand?

AI engines repeat outdated pricing, wrong ingredients, and misread positioning every day. Tell us what this answer gets wrong and we will include a correction review in your free AI Visibility Audit.

This answer is reproduced verbatim from the engine's API at collection time and may contain errors or outdated claims. It is presented as evidence of what AI engines tell buyers, not as medical or purchasing advice.

Is your brand missing from this answer?

Get your AI Visibility Audit: every buyer intent question you are losing, who wins them, and the sources that decide the answer.